Publication: Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia
Loading...
Identifiers
Date
2017-04-27
Authors
Gudiol, Carlota
Royo-Cebrecos, Cristina
Abdala, Edson
Akova, Murat
Alvarez, Rocio
Maestro-de la Calle, Guillermo
Cano, Angela
Cervera, Carlos
Clemente, Wanessa T.
Martin-Davila, Pilar
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Metrics
Export
Abstract
beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
Description
MeSH Terms
Klebsiella-pneumoniae
Piperacillin-tazobactam
Risk-factors
Bacteremia
Carbapenems
Therapy
Mortality
Outcomes
Cancer
Piperacillin-tazobactam
Risk-factors
Bacteremia
Carbapenems
Therapy
Mortality
Outcomes
Cancer
DeCS Terms
Carbapenémicos
Neoplasias
Piperacilina
Riesgo
Tazobactam
Terapéutica
Mortalidad
Neoplasias
Piperacilina
Riesgo
Tazobactam
Terapéutica
Mortalidad
CIE Terms
Keywords
ESBLs, Bloodstream infection, Neutropenia, Beta-lactam/beta-lactamase inhibitors, Mortality, Escherichia-coli
Citation
Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, et al. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00164-17